Evolving Practices in the Assessment of Medical Devices An Industry Perspective Adrian Griffin | April 2016.

Slides:



Advertisements
Similar presentations
Pricing and paying for medicines Ad Antonisse AstraZeneca BV April 2005.
Advertisements

1/16 Service Package for Life Science Start-Ups Regulatory, Reimbursement, Quality and Clinical Research In Europe and the USA UK Office: 27 Old Gloucester.
From Theory to Reality A Manufacturer’s View of Health Reform SEPAC March 2012.
The evolving role of real-world evidence to support policy and practice CADTH 2015.
Policy recommendations for wider implementation of telemedicine Peeter Ross, MD, PhD e-Health expert, Estonian eHealth Foundation, Estonia.
How can the Pharma Industry assist the NHS in constrained times? Can Pharma help with QIPP? PDIG meeting, 10 June 2010 Alison Clough Commercial & Communications.
APIs – global business developments Gian Mario Baccalini EFCG Board Member, Chairman of EFCG Pharma Business Committee President, B&P Development Srl,
HTA from an Industry Perspective Janey Shin, Director of Medical Affairs Johnson & Johnson Medical Companies CADTH, 2015.
HTA & Medical Devices: An International Perspective Christina Farup, MD, MS | April 2015.
Pharmacy & National Procurement Christine Gilmour Chief Pharmacist NHS Lanarkshire.
The Health Care Sector Analysts: Heather Hund and Emily Butler.
Paying Less By Purchasing Smarter Gerard Anderson, PhD Professor Johns Hopkins University.
Current Approaches in European Health Care Policy What models can balance the needs of payors and industry?
MRosenmöller– Health Financing & Fiscal Sustainability European Experience with Health Insurance and Challenges for the Future Workshop.
/ Selling to the NHS Ian Sandison.
Medicines Transparency Alliance01/10/2015 Availability of Medicines Anita Wagner Harvard Medical School & WHO Collaborating Center in Pharmaceutical Policy.
The competition between innovative and generic pharmaceutical companies intensified in the last decades. The models created by innovative pharmaceutical.
Summary: Biological Therapeutics for Rare Plasma Protein Disorders Workshop July 21, 2005 Mark Weinstein, Ph.D. Office of Blood Research and Review CBER,
HTA cooperation in the EU EPF workshop Jérôme Boehm 18 May 2010.
AIFA European Conference on Clinical Research for Decision Making Sergio Dompé - Farmindustria Rome, March 30th, 2007 Access to market by new medicines.
Integrate Risk Evaluation & Mitigation Strategies (REMS) with Health Management Craig Kephart, President & CEO Centric Health Resources, Inc. July 15,
NHS England New Structure and Industry Engagement Richard Stubbs Head of Commercial and International Innovation NHS England.
1 Evaluating & Applying What Works Best Leaders’ Project Policy Forum Kathy Buto, VP Health Policy April 24, 2008.
(Fortune, 2002, p. 16).  Competition  Barriers to Entry  Regulation.
Strictly confidential How to achieve sustainability in rapidly changing environment? Pavle Marjanović, Country Manager for Actavis Republic of Serbia and.
HSC 6636: Pharmaceuticals & Medical Technology 1 Dr. Lawrence West, Health Management and Informatics Department, University of Central Florida
Innovating out of the recession in the NHS Steve Barnett, Chief Executive NHS Confederation 28 th October 2009 Foundation Trust Network - Primary Care.
Consumers Have Spoken Job Creation The National Debt Healthcare Costs.
© Safeguarding public health Can Europe grow its Medtech industry and lead the world on medical device regulation? John Wilkinson 20 th September 2012.
Medical Technologies and Pharmaceuticals Industry Growth Centre CHAIR: Dr Bronwyn Evans Presentation Pack June 2015.
U.S. Medical Devices Market Outlook Research and Development Expected to be a Key Driver for Future Growth of the U.S. Medical Devices Market “Manufacturers'
What HIT Policy Changes Will Mean for MedTech October 22, 2004 Blair Childs Executive Vice President, Strategic Planning & Implementation.
Health Technology Assessment
Process mapping of registration to reimbursement for new pharmaceuticals in UK.
Patients access to investigational drugs Steinar Aamdal Dept. of Clinical Cancer Research Oslo University Hospital.
Science is leading the revolution in targeted, personalised therapies:
Structural Change in Pharmaceuticals: The Growth of Biologics and Emergence of Biosimilars Henry Grabowski Duke University Conference on Structural Change,
The HTA-Adoption (missing) Link for Medical Devices: Observations to Date Daria O’Reilly PhD Associate Professor, Dept. of Clinical Epidemiology & Biostatistics,
Methodological Issues in Implantable Medical Device(IMDs) Studies Abdallah ABOUIHIA Senior Statistician, Medtronic.
Gwendolyn Ryals, Look at Me Artwork from The Creative Center Janey Shin, Director, Real World Evidence Government Affairs and Market Access CADTH Symposium.
Category : Medical Devices All logos and Images mentioned on this slide belong to their respective owners.
Regulatory and Reimbursement Harmonization An Industry Perspective Adrian Griffin | April 2016.
Aarkstore - Metastatic Ovarian Cancer- Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015 Category : Pharmaceuticals and Healthcare.
Andy Passey September 23rd 2003 Advanced Wound Management in Europe: Market Overview and Critical Success Factors © 2003 Frost & Sullivan. All rights reserved.
Conferenceboard.ca Aligning, Foreseeing, and Optimizing HTA in Canada 2016 CADTH Symposium April 12, 2016 Dr. Gabriela Prada Director, Health Innovation.
The pharmaceutical market in Europe
“Disinvestment: What Does it Mean in the Canadian Context?” Public Payor Perspective CADTH Symposium April 2016 Chad Mitchell, MSc. Pharm A/Executive Director,
Regenerative Therapies KTN Meeting, Sheffield, April 2013 Paul Trueman, Smith & Nephew Securing Market Access for Regenerative Therapies.
Minimally Invasive Spine Market Current and Future Players Published: Jan 2017 Single User PDF: US$ 3500 Order this report by calling
ELECTROPHYSIOLOGY DEVICES MARKET GLOBAL BRIEFING 2017 INCLUDING: ABLATION CATHETERS, PACEMAKERS, IMPLANTABLE CARDIOVERTER DEFIBRILLATORS, CARDIAC RESYNCHRONIZATION.
CARDIAC ASSIST DEVICES MARKET GLOBAL BRIEFING 2017 INCLUDING: INTRA-AORTIC BALLOON PUMPS, VENTRICULAR ASSIST DEVICES AND ARTIFICIAL HEARTS. COVERING: ABBOTT.
iHEA 9th World Congress Sydney, July 8, 2013
The role of deals and business networks in innovation processes Implications for public procurement? Professor Per Ingvar Olsen.
Health Technology Assessment
Redefining Competition
BELEN MARTI - Iberia Market Access
Databridgemarketresearch.comdatabridgemarketresearch.com US : UK :
Click to edit Master title style 1 Global Industry Analysis Report Of Endoscopy Devices Market - Size, Trend, Share, Opportunity Analysis & Forecast,
Finland, a Global Testbed for Personalized Cancer Research?
An Increasing Demand for Prescription Drugs Drives Profitability
New economies: Scenarios with a likelihood >50% and impact
Internet Interconnection
Irish Medical Device Association John O’Dwyer, Chief Executive
Challenges and Solutions for the Private Healthcare Industry
An Industry Perspective Nicole Denjoy COCIR Secretary General
Innovative Medicines Initiative:
Healthcare Artificial Intelligence Market to Global Analysis and Forecasts By Offering (Hardware, Software, and Services), Technology (Deep Learning,
Dispensing Doctors’ Association 20 October 2016
Regulatory and Reimbursement Harmonization
Process mapping of registration to reimbursement for new pharmaceuticals in UK Description: A systematic methodology was developed in order to create the.
Presentation transcript:

Evolving Practices in the Assessment of Medical Devices An Industry Perspective Adrian Griffin | April 2016

2 The Medical Device Sector in Context Pharma Industry Medical Device Industry Products Rel. Prop. of HC spend Companies Systems spend roughly 2x as much on drugs than devices The FDA approved 1,453 drugs (to Dec ‘13) - EUCOMED reports more than 500,000 medical devices Innovative drug industry dominated by large & medium companies - MedTech comprised mainly of SMEs: EUCOMED report >25,000 Life of a branded medicine can be ~8-12 years – Commercial lifecycle of a device ~2-3 years REALITY for Devices: More products; shorter ROI window; chasing less HC spend

3 Complexity of Medical Device Pathways In Europe, and elsewhere Regulatory Always HTA Sometimes Reimbursement More often by procedure (DRG) Procurement Local not national

Context of HTA in Decision-Making Pharmaceuticals compared with Medical Devices PharmaceuticalsMedical Devices WHY Inform Pricing or Reimbursement No ‘routine’ Reimbursement Decision WHEN ASAP after Regulatory Approval Varies

5 Recognising the differences in HTA application between drugs and devices Regulatory Approval Reimbursement Coverage (DRG) National ContractLocal procurement Regional ContractCoverage (DRG) Local procurement HTA Local HTA Hospital HTA Local procurement

6 Which Medical Devices have HTA Evaluation? 2014: 365 National HTA reports published in Europe Reports were published in 12 European countries 80% of in 4 Countries - FR, ES, UK, and 51% of reports were published in France 365 HTA reports were published in (78%) looking at medical devices 28 (8%) looking at IVDs 29 (8%) looking at imaging equipment 22 (6%) others Statistic based on Synergus database

7 HTA influence Procurement influence Disconnect between evaluator and purchaser (1) Challenges with Traditional HTA of Devices Price falls on old technology as suppliers compete for smaller market Price difference between old and new increases, so relative value of Innovation falls Traditional HTA methods suggest disinvestment from new technology HTA puts downward pressure on price of innovation, so relative C-E improves against old technology Innovative Technology assessed by HTA as clinically and cost effective Innovation replaces older technology; “disinvestment” from old to new

8 Disconnect between evaluator and purchaser (2) Challenges with Evidence Extrapolation HTA seeks to evaluate all technologies by the methods / rigor applied to drugs –Demand evidence of value before adoption; seek certainty of benefit & value But users procure devices like commodities; –Demand discounts, price/volume agreements, low barriers to entry for competition –Guaranteed ‘exclusivity’ period 5 years data exclusivity in US 10 years in Europe ‘Me-too’ products (not generics) have to cross similar evidence hurdle –Provides opportunity for return on innovation Eco-system incentivises evidence generation Pharmaceuticals –There is no “data exclusivity” Innovator generates evidence for payer Purchasers take evidence from the first entry and extrapolates to class ‘Me-too’ products have lower hurdle - drive competition on price –First mover disincentive Eco-system undermines the incentive for evidence generation Devices

9 Opportunities Redefine procurement –Value based, rather than price –BCG/EUCOMED project underway Support use of local (hospital) HTA where decisions are made –European AdHopHTA project Recognise evidentiary contexts –Devices - Outcomes often accrue after use –Drugs – outcomes often accrue during use So routes to evidence may well (logically) differ

10 Examples of Change Medtronic Biosense Webster (J&J) St Jude Medical Tyrx Mesh sleeve for cardiac Implants: Medtronic to cover cost of infections if infection rate is not lowered compared with rate in procedures without it Thermocool catheter for AF: discount on devices used in a repeat procedure if a patient initially treated with those products returns within a year Quadra heart rhythm device: %age rebate for a device if revision surgery is needed in the first year after implant due to problems with the company’s Quartet lead wire

11 Thank You